Guggenheim raised the firm’s price target on AbbVie (ABBV) to $242 from $227 and keeps a Buy rating on the shares after updating the firm’s model ahead of the company’s Q3 earnings release due on October 31. The firm believes investors continue to view AbbVie as “a relatively easy story to support” given the solid visibility the company has on its topline and bottom line growth outlook, the analyst says in a preview.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABBV:
- AbbVie completes acquisition of Gilgamesh Pharmaceuticals’ bretisilocin
- AbbVie price target raised to $250 from $236 at Raymond James
- 3 Best Dividend Aristocrat Stocks to Buy Now, 10/16/2025
- AbbVie’s Phase 2 Study on CLL/SLL Treatment: Key Updates and Market Impact
- AbbVie’s Venetoclax Study Completion: A Potential Boost for Investors